Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - Citius Pharmaceuticals, Inc. | ctxr_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
_________________________________
Date of Report (Date of earliest event reported): March 7, 2016
Citius Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Nevada | 000-55532 | 27-3425913 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
63 Great Road Maynard, MA | 01754 | |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (978) 938-0338
_______________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On March 7, 2016 Citius Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company has entered into a non-binding letter of intent to acquire all of the outstanding shares of capital stock of Leonard-Meron Biosciences, Inc.
A copy of the press release that discusses this matter is filed as Exhibit 99.1 to, and incorporated by reference in, this report. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description of Exhibit Press Release dated March 7, 2016
99.1
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CITIUS PHARMACEUTICALS, INC. | |||
Date: March 10, 2016 | By: | /s/ Leonard Mazur | |
Leonard Mazur | |||
|
| President and Chief Executive Officer |
|
3